Vigil Neuroscience, Inc.

Equities

VIGL

US92673K1088

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 29/05/2024 am IST			5-day change	1st Jan Change
3.31 ^USD	-8.82%		-5.43%	-2.07%

07/05	Vigil Neuroscience, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
17/04	Vigil Neuroscience, Inc. Presents Key Findings from Illuminate & Ignite Studies in ALSP At the 2024 American Academy of Neurology Annual Meeting	CI

Vigil Neuroscience, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022

March 21, 2023 at 04:48 pm IST

Vigil Neuroscience, Inc. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported net loss was USD 68.31 million compared to USD 43.28 million a year ago. Basic loss per share from continuing operations was USD 2.16 compared to USD 28.26 a year ago.

Latest news about Vigil Neuroscience, Inc.

Vigil Neuroscience, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	08/05	CI
Vigil Neuroscience, Inc. Presents Key Findings from Illuminate & Ignite Studies in ALSP At the 2024 American Academy of Neurology Annual Meeting	18/04	CI
Wedbush Trims Vigil Neuroscience Price Target to $22 From $23, Maintains Outperform Rating	26/03	MT
Vigil Neuroscience, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	26/03	CI
Vigil Neuroscience, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	26/03	CI
North American Morning Briefing : Markets Steady -2-	26/03	DJ
Vigil Neuroscience Names Petra Kaufmann Chief Medical Officer	20/03	MT
Vigil Neuroscience, Inc. Announces Executive Changes	20/03	CI
North American Morning Briefing : Stock Futures -2-	19/03	DJ
Transcript : Vigil Neuroscience, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-11-2024 07:30 AM	11/01
North American Morning Briefing : S&P 500 Futures -2-	20/12	DJ
Morgan Stanley Downgrades Vigil Neuroscience to Underweight From Equalweight, Cuts Price Target to $4 From $13	19/12	MT
Vigil Neuroscience Reports Positive Interm Results for Treatment of Axonal Spheroids and Pigmented Glia	17/11	MT
Transcript : Vigil Neuroscience, Inc. - Special Call	17/11
Vigil Neuroscience, Inc. Reports Positive Interim Data from Phase 2 Ignite Proof-Of-Concept Clinical Trial Evaluating Iluzanebart as a Treatment for ALSP and from Ongoing Natural History Study ILLUMINATE	17/11	CI
Vigil Neuroscience, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	07/11	CI
JMP Securities Starts Vigil Neuroscience With Market Outperform Rating, Price Target is $23	18/23/18	MT
Vigil Neuroscience Shares Rise After First Participant Dosed in Phase 1 Trial of Potential Alzheimer's Disease Treatment	17/23/17	MT
Vigil Neuroscience Says First Participant Dosed in Phase 1 Trial of Potential Alzheimer's Disease Treatment	17/23/17	MT
Vigil Neuroscience, Inc. Announces First Participant Dosed in Phase 1 Clinical Trial in Healthy Volunteers Evaluating Vv-3927, a Small Molecule Trem2 Agonist, for Potential Treatment of Alzheimer's Disease	17/23/17	CI
Vigil Neuroscience, Inc Provides an Update on the Small Molecule TREM2 Agonist, VG-3927	13/23/13	CI
Vigil Says Orphan Drug Designation Application for Proposed Leukoencephalopathy Therapy Secured European Positive Opinion	26/23/26	MT
Vigil Neuroscience, Inc. Receives Positive Opinion from European Medicines Agency on Orphan Drug Designation for Vgl101 for the Treatment of ALSP	26/23/26	CI
Vigil Neuroscience, Inc.(NasdaqGS:VIGL) added to S&P Global BMI Index	18/23/18	CI
Transcript : Vigil Neuroscience, Inc. - Special Call	13/23/13

Chart Vigil Neuroscience, Inc.

Duration

Period

More charts

Company Profile

Vigil Neuroscience, Inc. is a clinical-stage biotechnology company. The Company is focused on developing treatments for both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities in its efforts to develop precision-based therapies to improve the lives of patients and their families. Its lead clinical candidate, VGL101 (iluzanebart), is a fully human monoclonal antibody TREM2 agonist that is being studied in a Phase 2 proof-of-concept trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia. The Company is also developing VG-3927, its orally available small molecule TREM2 agonist program to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimerâs disease in genetically defined subpopulations.

Sector

Biotechnology & Medical Research

Calendar

05/06/2024 - Annual General Meeting

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

3.31 USD

Average target price

16.75 USD

Spread / Average Target

+406.04%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
VIGIL NEUROSCIENCE, INC.	-2.07%	124M
MODERNA, INC.	+54.05%	58.71B
IQVIA HOLDINGS INC.	-2.02%	41.31B
LONZA GROUP AG	+40.01%	39.2B
CELLTRION, INC.	-10.22%	27.4B
ICON PUBLIC LIMITED COMPANY	+13.42%	26.55B
ALNYLAM PHARMACEUTICALS, INC.	-21.60%	18.98B
BIO-TECHNE CORPORATION	+2.89%	12.51B
UNITED THERAPEUTICS CORPORATION	+22.40%	11.94B
MEDPACE HOLDINGS, INC.	+27.49%	12.08B

Other Biotechnology & Medical Research